Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another institution now enrolling Lympho patients...
Main Line Health in Pennsylvania. Treatment will be at their hospital in Lankenau.
United States, Pennsylvania
Ned Carp, M.D. - Recruiting
Philadelphia, Pennsylvania, United States, 19096
Contact: Ro Tucci, MSN, AOCN
610-645-2680
tucciro@mlhs.org
Link: http://clinicaltrials.gov/show/NCT00671918
Funny line from the movie Wargames...
"Remember you told me to tell you when you were acting rudely and insensitively? Remember that? You're doing it right now."
DDbuyer
privateinv... welcome to the board...
July is probably optimistic. The concensus of opinions seems to be that NEOP will most likely flounder around and trade sideways until interim results come out... or at least until the word trickles out.
Interims aren't expected until perhaps September. Barring unexpected news (RIGS, Quantix, etc.), most of us are resolved to just biding our time and waiting it out.
DDbuyer
"I definitely oppose that idea" - tonoos
OK, skip it then. Matters not to me...
DDbuyer
I don't know why sources aren't consistent...
I'd also like to see it on Nasdag (and everywhere else).
When I checked CNBC.com a couple months back to verify the CALPERS holdings, the Medical Strategy holding wasn't listed... and NEOP does seem to fit their target investment. We'll see if it eventually shows up elsewhere...
DDbuyer
The basher will find us eventually...
Now that we have things set up, I wouldn't have a problem putting a post on IV and RB with a link steering the lurkers here.
On iHub we can delete the "kool aid drinking, circle jerk" posts instantly, and keep things on an adult level.
DDbuyer
NEOP board & lurkers...
Lotb, we've always had lurkers. We had them on RB. The difference was that IV gave us a viewer count, so we could quantify how many were in the shadows...
I'm not going to post on more than one board because it's time consuming. Lurkers go where the chatter is. No matter where the group goes, the lurkers will follow. They want to stay abreast of the latest buzz...
DDbuyer
New institutional investor
CNBC.com shows a new institutional player on their list of holders: Medical Strategy Investment Advisors holding 531,400 shares @ of June 28th.
They also show a new mutual fund called VCH Expert Bio Tech holding 338,400 shares.
I looked it up, and VCH is a fund managed by Medical Strategy. I'm not sure if the 338,400 is part of the 531,400 total, or if they are separate funds.
Here's the link: http://www.cnbc.com/id/15837275?q=neop
Medical Strategy is based in Europe.
DDbuyer
tonoos - RE: DD blog
I'm working on that now... I have to upload some graphics to their Image hosting server first, but will do it shortly.
DDbuyer
Lotb & simple...
You guys need to think about sharing some of that info on the board, that was mentioned in private to me about the Cardinal attendees.
That's priceless... and just the kind of stuff we've all been hoping was happening behind the scenes. But I'll leave it up to you to decide to share... it's your call.
DDbuyer
I wonder if VV does their own earnings analysis...
... or if they are basing their earning projections on other analysts such as WBB and Dutton.
DDbuyer
VectorVest Stock Analysis
I forgot that I requested this the other day from VectorVest. It's been sitting in my e-mail. It's just FYI and NEOP related reading...
Neoprobe Corp. as of 6/23/2008
Summary Analysis
NEOP is overvalued compared to its Price of $0.70 per share, has below average safety, and is currently rated a Buy.
Drug (Biomedical\Genetic)
Detailed Analysis
Capital Appreciation
Value: Value is a measure of a stock's current worth. NEOP has a current Value of $0.53 per share. Therefore, it is overvalued compared to its Price of $0.70 per share. Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitability increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock's Price and Value always will converge.
RV (Relative Value): RV is an indicator of long-term price appreciation potential. NEOP has an RV of 1.23, which is good on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.
RS (Relative Safety): RS is an indicator of risk. NEOP has an RS rating of 0.74, which is poor on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company's financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance.
RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock's price trend. NEOP has a Relative Timing rating of 1.48, which is excellent on a scale of 0.00 to 2.00. RT is computed from an analysis of the direction, magnitude, and dynamics of a stock's price movements over one day, one week, one quarter and one year time periods. Once a stock's price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00.
VST (VST-Vector): VST is the master indicator for ranking every stock in the VectorVest database. NEOP has a VST rating of 1.21, which is good on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price.
Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. NEOP has a Buy recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets.
Stop (Stop-Price): Stop is an indicator of when to sell a long position or cover a short position. NEOP has a Stop of $0.60 per share. This is $0.1 below NEOP's current closing Price. A stock's Stop is computed from a 13 week moving average of its closing prices, and is fine-tuned according to the stock's fundamentals. High RV, high RS stocks have lower Stops, and low RV, low RS stocks have higher Stops. In the VectorVest system, a stock gets a 'B' or 'H' recommendation if its Price is above its Stop and an 'S' recommendation if its Price is below its Stop.
GRT (Earnings Growth Rate): GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. NEOP has a forecasted Earnings Growth Rate of 37.00%, which VectorVest considers to be excellent. GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock's future price trend. If a stock's GRT trend is upward, the stock's price will likely rise. If GRT is trending downward, the stock's Price will probably fall. VectorVest favors the purchase of stocks whose GRT is rising and is greater than the sum of current inflation and interest rates, (10.11%).
EPS (Earnings per Share): EPS stands for leading 12 months Earnings Per Share. NEOP has a forecasted EPS of $0.02 per share. VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts.
P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings. NEOP has a P/E of 35.00. This ratio may be deemed to be high or low depending upon your frame of reference. The average P/E of all the stocks in the VectorVest database is 33.25. P/E is computed daily using the formula: P/E = Price/EPS.
EY (Earnings Yield): EY reflects earnings per share as a percent of Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may be used in place of P/E as a measure of valuation. EY has the advantages that it is always determinate and can reflect negative earnings. NEOP has an EY of 2.86 percent. This is below the current average of 3.01% for all the stocks in the VectorVest database. EY equals 100 x (EPS/Price).
GPE (Growth to P/E Ratio): GPE is another popular measure of stock valuation. It compares earnings growth rate to P/E ratio. NEOP has a GPE rating of 1.06. High growth stocks are believed to be able to justify high P/E ratios. A stock is commonly considered to be undervalued when GPE is greater than 1.00 and overvalued when GPE is below 1.00. Unfortunately, this rule of thumb does not take into account the effect of interest rates on P/E ratios. The operative GPE ratio of 1.00 is valid when and only when interest rates equal 10%. With long-term interest rates currently at 5.91%, the operative GPE ratio is 0.35. Therefore, NEOP may be considered to be undervalued.
Dividend Information
DIV (Dividend): VectorVest reports annual, regular, cash dividends as indicated by the most recent payments. Special distributions, one-time payments, stock dividends, etc., are not generally included in DIV. NEOP does not pay a dividend.
DY (Dividend Yield): DY reflects dividend per share as a percent of Price. NEOP does not pay a dividend, so it does not have a Dividend Yield rating. . DY equals 100 x (DIV/Price). It is useful to compare DY with EY. If DY is not significantly lower than EY, the dividend payment may be in jeopardy.
DS (Dividend Safety): DS is an indicator of the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future. NEOP does not pay a dividend, so it does not have a Dividend Safety rating . Stocks with DS values above 75 typically have RS values well above 1.00 and EY levels that are much higher than DY.
DG (Dividend Growth Rate): Dividend Growth is a subtle yet important indicator of a company's financial performance. It also provides some insight into the board's outlook on the company's ability to increase earnings. NEOP does not pay a dividend, so it does not have a Dividend Growth rating .
YSG (YSG-Vector): YSG is an indicator which combines DIV, DY and DG into a single value, and allows direct comparison of all dividend-paying stocks in the database. NEOP does not pay a dividend, so it does not have a YSG rating . Stocks with the highest YSG values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for above average current income and long-term growth.
Price-Volume Data
Price: NEOP closed on 6/23/2008 at $0.70 per share
Open: NEOP opened trading at a price of $0.73 per share on 6/23/2008.
High: NEOP traded at a High price of $0.74 per share on 6/23/2008.
Low: NEOP traded at a Low price of $0.70 per share on 6/23/2008
Close: NEOP closed trading at price $0.70 per share on 6/23/2008. (Close is also called Price in the VectorVest system)
Range: Range reflects the difference between the High and Low prices for the day. NEOP traded with a range of $0.05 per share on 6/23/2008.
$Change: NEOP closed down 0.05 from the prior day's closing Price.
%PRC: NEOP's Price changed -6.67% from the prior day's closing price.
Volume: NEOP traded 117,046 shares on 6/23/2008.
AvgVol: AvgVol is the 50 day moving average of daily volume as computed by VectorVest. NEOP has an AvgVol of 196,600 shares traded per day.
%Vol: %Vol reflects the percent change in today's trading volume as compared to the AvgVol. %Vol equals ((Volume - AvgVol) / AvgVol ) * 100. NEOP had a %Vol of -40.46% on 6/23/2008
CI (Comfort Index): CI is an indicator which reflects a stock's ability to resist severe and/or lengthy price declines. NEOP has a CI rating of 1.58, which is excellent on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock's long-term price history. VectorVest advocates the purchase of high CI stocks.
Sales / Market Capitalization Information
Sales: NEOP has annual sales of $7,000,000
Sales Growth: Sales Growth is the Sales Growth Rate in percent over the last 12 months. NEOP has a Sales Growth of 19.00% per year. This is very good. Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company's operations.
Sales Per Share (SPS): NEOP has annual sales of $0.10 per share. SPS can be used as a measure of valuation when comparing stocks within an Industry Group.
Price to Sales Ratio (P/S): NEOP has a P/S of 6.73. This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group.
Shares: NEOP has 68,000,000 shares of stock outstanding.
Market Capitalization: NEOP has a Market Capitalization of $48,000,000. Market Capitalization is calculated by multiplying price times shares outstanding.
Business: Neoprobe Corp., (NEOP) Neoprobe Corporation, a biomedical company, engages in the development and commercialization of surgical and diagnostic products. It offers gamma detection device systems that consist of hand-held detector probes and a control unit.
Business Sector: NEOP has been assigned to the Drug Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
Industry Group: NEOP has been assigned to the Drug (Biomedical\Genetic) Industry Group. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
Bashers will be here too...
The difference is that abusive posts can be deleted instantly here on iHub. We don't have to wait on a moderator to review it and delete it, like on RB and IV.
It should be much easier to maintain civility and chat amongst ourselves without all the cursing, insults and personal attacks from the bashers.
DDbuyer
I know z3 asked the question...
... but I don't think anyone ever answered about attending the SHM meeting. I sure would like to know if Montaur had a rep there. I'd also like to know if someone found out the current score in the Lympho trials.
DDbuyer
OT: I did, but I hesitated. Didn't pull the trigger until it broke under $180.
DDbuyer
Time will tell... there are some differences, like a limit of 15 posts per day but that's no biggie. I'm going to check around and look at all the features.
SHM results:
Neoprobe Announces Annual Meeting Results
Thursday June 26, 2:11 pm ET
CEO Provides Business Update
DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP - News), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, announced today that its stockholders re-elected Carl J. Aschinger, Jr., Owen E. Johnson, M.D. and Fred B. Miller as Directors of the Company for terms ending at the 2011 Annual Meeting.
In addition, Neoprobe’s stockholders approved an amendment to the Company’s 2002 Stock Incentive Plan to increase the number of shares issuable under the Plan from 5,000,000 to 7,000,000 shares.
David Bupp, Neoprobe’s President and CEO, provided the stockholders at the Company’s 2008 Annual Meeting with a business update. During his presentation, which followed the formal portion of the meeting, Mr. Bupp reviewed the Company’s activities over the past year highlighting the following milestones:
Completion of Phase 2 Lymphoseek® clinical study in patients with breast cancer or melanoma that exceeded performance objectives
FDA clearance for first Phase 3 study of Lymphoseek in breast or melanoma patients
Enrollment of patients in first Phase 3 study of Lymphoseek
Marketing and distribution agreement for Lymphoseek in the U.S. with the dominant nuclear pharmacy company.
Extension of gamma detection device marketing agreement with the Company’s primary device marketing partner through 2013
Commenced EU regulatory initiative for Lymphoseek
$14 million in capital committed to fund Lymphoseek commercial development
Neoprobe GDS (Model 2300) gamma detection system console launched
Regulatory initiative for RIGScan® CR commenced in EU
In conclusion, Mr. Bupp thanked the stockholders for their continuing support of the Company and its business activities.
Wee bit of news:
Neoprobe Introduces Enhanced Gamma Detection SystemLast update: 6/24/2008 10:15:01 AMNew Control Unit Features Internal Wireless Link
DUBLIN, Ohio, Jun 24, 2008 (BUSINESS WIRE) -- Neoprobe Corporation (NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it has recently introduced an enhanced gamma detection control unit, the Neoprobe(R) GDS (Model 2300), in connection with the Company's marketing partner, Ethicon Endo-Surgery, Inc. (a Johnson & Johnson company).
The Neoprobe GDS control unit contains internal circuitry that enables it to communicate with Neoprobe's family of wireless probes without the necessity of an external adapter. Neoprobe's wireless gamma detection products are based on Bluetooth(R) technology and eliminate cumbersome cables that can unnecessarily complicate the surgical field.
Neoprobe's wireless probes are available with either straight or angled tips and can also be used with all previous models of the Company's neo2000(R) control unit (Models 2000, 2100 and 2200) using an external serial port adapter. Neoprobe's gamma detection products are widely used by cancer surgeons in a procedure called Sentinel Lymph Node Biopsy (SLNB) or Intraoperative Lymphatic Mapping (ILM).
David Bupp, Neoprobe's President and CEO, said, "We are excited by this addition to our gamma detection product line. Our wireless gamma detection probes have been well received in the marketplace and placements over the last eighteen months have exceeded our initial expectations. The improvements to our wireless product offerings, coupled with our clinical development program for the lymphatic tissue tracing agent Lymphoseek(R), further demonstrate our ongoing commitment to assist physicians in providing state of the art treatment for cancer patients."
You are using the Ameritrade summary quotes.
You need to try and use the L2 quotes in order to get the accurate quotes. For some reason the summary doesn't always pick up the closest BIDS and ASKS... but L2 will.
DDbuyer